Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ophthalmology

Free Subscription Articles published in Lancet Retrieve available abstracts of 14 articles: HTML format

Single Articles

May 2023
1. DMUCHOWSKA DA, Obuchowska I, Konopinska J
   Immediate versus delayed sequential bilateral cataract surgery.
   Lancet. 2023 May 15:S0140-6736(23)00692-X. doi: 10.1016/S0140-6736(23)00692.
   PubMed    
   
   
   
2. SPEKREIJSE L, Simons R, Winkens B, van den Biggelaar F, et al
   Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
   Lancet. 2023 May 15:S0140-6736(23)00525-1. doi: 10.1016/S0140-6736(23)00525.
   PubMed     Abstract available
   
   
   March 2023
3. GUYMER RH, Campbell TG
   Age-related macular degeneration.
   Lancet. 2023 Mar 27:S0140-6736(22)02609-5. doi: 10.1016/S0140-6736(22)02609.
   PubMed     Abstract available
   
   
   December 2022
4. CICINELLI MV, Buchan JC, Nicholson M, Varadaraj V, et al
   Cataracts.
   Lancet. 2022 Dec 21:S0140-6736(22)01839-6. doi: 10.1016/S0140-6736(22)01839.
   PubMed     Abstract available
   
   
   September 2022
5. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
   Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
   Lancet. 2022;400:808-809.
   PubMed    
   
   
   
6. DYBALL S, Parker B, Bruce IN
   Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
   Lancet. 2022;400:807-808.
   PubMed    
   
   
   August 2022
7. BAGENAL J, Khanna R, Hawkes S
   Not misogynistic but myopic: the new women's health strategy in England.
   Lancet. 2022 Aug 10. pii: S0140-6736(22)01486.
   PubMed    
   
   
   January 2022
8. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
   Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
   Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
   PubMed     Abstract available
   
   
   
9. HEIER JS, Khanani AM, Quezada Ruiz C, Basu K, et al
   Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
   Lancet. 2022 Jan 21. pii: S0140-6736(22)00010.
   PubMed     Abstract available
   
   
   
10. CHIA MA, Keane PA
    Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00105.
    PubMed    
    
    
    
11. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    PubMed    
    
    
    
12. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    PubMed     Abstract available
    
    
    
13. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    PubMed    
    
    
    October 2021
14. AYADI K, Gallaoui S, Ben Nsir A
    Pituitary apoplexy, but not as we thought: a xanthogranuloma rather than an adenoma.
    Lancet. 2021;398:e16.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: